TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04506450

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral nerve block
Description: In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during hip surgery.~Lumbar plexus and sciatic nerve blocks will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle and plantar or dorsal flexion of the foot will be detected respectively. For both, a mixture of mepivacaine and levobupivacaine will be injected.~Lateral femoral cutaneous nerve block will be performed with the ultrasound technique. After identifying the nerve, a needle will be inserted with an in plane approach and will be injected.~Lateral branch of iliohypogastric nerve block will be executed with the De Visme approach. Along the iliac crest (range between 7 and 11 cm from the anterior superior iliac spine) a needle will be inserted until bone contact is found. Then a mixture of mepivacaine and levobupivacaine will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: In this group, spinal anesthesia will be performed to ensure anesthesia during surgery, while lumbar plexus block will be performed to ensure postoperative analgesia Spinal anesthesia will be performed with a 25 G needle and 12 mg 0.5% levobupivacaine will be injected.~Lumbar plexus block will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle will be detected. 20 ml 0.5% levobupivacaine will be injected.
Study: NCT02855294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COC containing 30 μg of EE and 3mg of drospirenone
Description: treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of pill treatment followed by a 1-week pill-free period.
Study: NCT01787604

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic Root Reimplantation Procedure
Description: Modified Florida Sleeve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic Valve Reimplantation Procedure
Description: David I
Study: NCT01466816

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: test meals with various fatty acid compositions
Description: Three different milkshakes with a U13C palmitate tracer added

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: test meals with various fatty acid compositions
Description: Three different milkshakes with a U13C palmitate tracer added

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: test meals with various fatty acid compositions
Description: Three different milkshakes with a U13C palmitate tracer added
Study: NCT03229330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-level Light Therapy
Description: Low-level Light Therapy 660nm (red laser), 1 to 3 Joules, irradiation time and number of points varied.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Topical treatment: essential fatty oil, hydrogel, papain gel, petrolatum gauze, calcium or silver alginate, zinc oxide and barrier cream; and high compression bandage SurePress

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Topical treatment: essential fatty oil, hydrogel, papain gel, petrolatum gauze, calcium or silver alginate, zinc oxide and barrier cream; and high compression bandage SurePress
Study: NCT03773744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad-MAGEA3
Description: Adenovirus vaccine expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad-MAGEA3
Description: Adenovirus vaccine expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG1-MAGEA3
Description: MG1 Maraba oncolytic virus expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG1-MAGEA3
Description: MG1 Maraba oncolytic virus expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: monoclonal antibody; checkpoint inhibitor of PD1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: monoclonal antibody; checkpoint inhibitor of PD1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: low-dose chemotherapy
Study: NCT02227160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 weekly group meetings
Description: 10 weekly group meetings with up to five other men and women at Grady Health System

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient counseling and support groups
Description: Usual mental health care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outpatient counseling and support groups
Description: Usual mental health care
Study: NCT02318329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPA144
Description: FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPA144
Description: FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPA144
Description: FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.
Study: NCT01679119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750mg/m2 IV, given day 1
Study: NCT06702540

Intervention type: DEVICE
Intervention: Biosensor chip
Description: An electronic platform measuring the impedance variation between microelectrodes is used upon capturing the target biomolecule by a selective bioprobe previously grafted over the biosensor surface. The required sensitivity will be achieved by operating the biosensor in lock-in mode, which ensures the highest resolution in tracking amplitude and phase variations of impedance signals.

Intervention type: DEVICE
Intervention: Biosensor chip
Description: An electronic platform measuring the impedance variation between microelectrodes is used upon capturing the target biomolecule by a selective bioprobe previously grafted over the biosensor surface. The required sensitivity will be achieved by operating the biosensor in lock-in mode, which ensures the highest resolution in tracking amplitude and phase variations of impedance signals.
Study: NCT02300064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee-extensor exercise test
Description: Steady-state, single leg knee-extensor exercise at 20 Watts for 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee-extensor exercise test
Description: Steady-state, single leg knee-extensor exercise at 20 Watts for 10 minutes
Study: NCT04578548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2737
Description: Capsules administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLPG2737
Description: Capsules administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules administered orally
Study: NCT01679119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750mg/m2 IV, given day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine 1.4mg/m2(max 2mg)IV given day 1
Study: NCT03608072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: 3 sequential dose groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: 3 sequential dose groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: 3 sequential dose groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 sequential dose groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 sequential dose groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 sequential dose groups
Study: NCT00555399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Phase I/Arm 1: Level 0 = 300 mg PO x 14 days; Level I = 400 mg PO x 14 days; Level II = 500 mg PO x 14 days.~Phase I/Arm 3: Level -II = 300 mg PO x 14 days; Level -I = 400 mg PO x 14 days; Level 0 = 400 mg PO x 14 days; Level I = 500 mg PO x 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Phase I/Arm 1: Level 0 = 300 mg PO x 14 days; Level I = 400 mg PO x 14 days; Level II = 500 mg PO x 14 days.~Phase I/Arm 3: Level -II = 300 mg PO x 14 days; Level -I = 400 mg PO x 14 days; Level 0 = 400 mg PO x 14 days; Level I = 500 mg PO x 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Phase I/Arm 1: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 2: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 3: Level -II = 100 mg/m\^2/day PO x 21 days; Level -I = 100 mg/m\^2/day PO x 21 days; Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Phase I/Arm 1: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 2: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 3: Level -II = 100 mg/m\^2/day PO x 21 days; Level -I = 100 mg/m\^2/day PO x 21 days; Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Phase I/Arm 1: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 2: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 3: Level -II = 100 mg/m\^2/day PO x 21 days; Level -I = 100 mg/m\^2/day PO x 21 days; Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical Resection
Description: Surgical Resection for recurrent Glioblastoma Multiforme

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Phase I/Arm 2: All Levels = 150 mg/m2/day PO X 14 days.~Phase I/Arm 3: Level 0 = 150 mg/m2/day PO X 14 days; Level I = 150 mg/m2/day PO X 14 days; Level -I = 125 mg/m2/day PO X 14 days; Level -II = 125 mg/m2/day PO X 14 days; Level -III = 100 mg/m2/day PO X 14 days.
Study: NCT02300064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise test with restricting/releasing blood flow
Description: 10 minute submaximal (20 Watts) single leg knee-extensor exercise with blood flow clamped 10-15% lower by arterial infustion of phenylephrine; 10 minute passive single leg knee-extensor exercise with blood flow matched to the 20 Watt work rate level by arterial adenosine infusion; 10 minute seated rest with blood flow matched to the 20 Watt work rate level by adenosine infusion. Each test separated by at least 30 minutes rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise test with restricting/releasing blood flow
Description: 10 minute submaximal (20 Watts) single leg knee-extensor exercise with blood flow clamped 10-15% lower by arterial infustion of phenylephrine; 10 minute passive single leg knee-extensor exercise with blood flow matched to the 20 Watt work rate level by arterial adenosine infusion; 10 minute seated rest with blood flow matched to the 20 Watt work rate level by adenosine infusion. Each test separated by at least 30 minutes rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise test with variable oxygen concentration and MRI
Description: Two bouts of single leg knee-extensor exercise to maximal effort breathing regular air (21% oxygen) or 100% oxygen through a mouthpiece, with a 90 minute rest period between each bout. The same experiment performed again on a separate day in an magnetic resonance imaging (MRI) machine
Study: NCT00555399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Phase I/Arm 2: All Levels = 150 mg/m2/day PO X 14 days.~Phase I/Arm 3: Level 0 = 150 mg/m2/day PO X 14 days; Level I = 150 mg/m2/day PO X 14 days; Level -I = 125 mg/m2/day PO X 14 days; Level -II = 125 mg/m2/day PO X 14 days; Level -III = 100 mg/m2/day PO X 14 days.
Study: NCT01679119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4mg/m2(max 2mg)IV given day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone 100mg OD Oral given days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 100mg OD Oral given days 1-5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375mg/m2 IV given day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m2 IV given day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Inotuzumab Ozogamicin 0.8mg/m2 IV given on day 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine up to 1g/m2 IV given day 1 and day 8 (Patients with ECOG PS 0-1: starting dose: 875mg/m2 (1st cycle). If tolerated can be escalated to 1g/m2 in cycle 2 and subsequent cycles. Patients with ECOG PS 2: starting dose 750mg/m2 (1st cycle). If tolerated can be escalated to 875mg/m2 in cycle 2 and then escalated to 1g/m2 in cycle 3 and subsequent cycles.)
Study: NCT02300064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise test with variable oxygen concentration and MRI
Description: Two bouts of single leg knee-extensor exercise to maximal effort breathing regular air (21% oxygen) or 100% oxygen through a mouthpiece, with a 90 minute rest period between each bout. The same experiment performed again on a separate day in an magnetic resonance imaging (MRI) machine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise test with oral antioxidant or placebo cocktail
Description: Antioxidants (Vitamin E - 400 international units, Vitamin C - 1000 milligrams and Alpha lipoic acid - 600 milligrams) or matching placebo capsules administered orally followed by femoral nerve stimulation and single leg knee-extensor exercise for 30 minutes at 50% maximum effort

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise test with oral antioxidant or placebo cocktail
Description: Antioxidants (Vitamin E - 400 international units, Vitamin C - 1000 milligrams and Alpha lipoic acid - 600 milligrams) or matching placebo capsules administered orally followed by femoral nerve stimulation and single leg knee-extensor exercise for 30 minutes at 50% maximum effort
Study: NCT02430935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training
Description: Cognitive Adaptation Training (CAT) is a manual-driven standardized approach that uses environmental supports to improve multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia. Interventions for each functional deficit are based on two dimensions 1) level of impairment in executive functions (determined by neurocognitive tests) and 2) whether the overt behavior of the individual is characterized more by apathy (poverty of speech/movement/inability to initiate and follow through on behavioral sequences), disinhibition (distractibility/behavior which is highly cue-driven) or a combination of these styles (based on the Frontal Lobe Personality Scale (FLOPS).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action Based Cognitive Remediation
Description: ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
Study: NCT01642888

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-Tb
Description: The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 T.U. Tuberculin PPD RT 23 SSI
Description: The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
Study: NCT03852381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Paresthesia-based SCS(PB-SCS), with stimulating frequencies between 30 to 80 Hz that confer a tingling sensation. Three different paresthesia-free SCS (PF-SCS) modes that use frequencies in the range of 400-10,000 Hz include Burst, High Frequency stimulation at 1.2 kHz and High Density stimulation at 400 Hz.
Study: NCT04382118

Intervention type: OTHER
Intervention: Data collection from routine medical records
Description: Data collection from routine medical records (clinical and radiological data)

Intervention type: OTHER
Intervention: Data collection from routine medical records
Description: Data collection from routine medical records (clinical and radiological data)
Study: NCT01886547

Intervention type: OTHER
Intervention: Prostate health screening
Study: NCT04010617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pharyngeal Electrical Stimulation (PES)
Description: PES will be delivered by a commercial device (Phagenyx, Phagenesis Ltd, Manchester, UK), which comprises a nasogastric feeding catheter that houses stimulation ring-electrodes and a computerised base station that delivers stimulation in the range 1-50 mA at 5 Hz.
Study: NCT01641887

Intervention type: OTHER
Intervention: Decision Aid
Description: Patients will use a decision aid administered on a computer.
Study: NCT04624698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent Inject Implantation
Description: Subjects will be implanted with the iStent Injection Micro-Bypass device
Study: NCT02310438

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Instrumental Music Performance
Description: The same instruments are selected and used with each participant. They are spatially arranged for them to play in their home in a way that addresses the target movement, for example elbow flexion and extension. The music therapist plays specific musical patterns live on a guitar for each exercise whilst the participant plays specific patterns on the instruments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Instrumental Music Performance
Description: The same instruments are selected and used with each participant. They are spatially arranged for them to play in their home in a way that addresses the target movement, for example elbow flexion and extension. The music therapist plays specific musical patterns live on a guitar for each exercise whilst the participant plays specific patterns on the instruments.
Study: NCT02277626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro Flo 5000
Description: Airway clearance device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incourage Vest System
Description: Airway Clearance Device
Study: NCT04877301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Description: Ultrasound guidance used to facilitate insertion of PIV catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-ultrasound guidance
Description: Ultrasound guidance will not be used for insertion of PIV catheter
Study: NCT03440632

Intervention type: DEVICE
Group type: OTHER
Intervention: FES
Description: Functional electrical stimulation of the ankle dorsiflexors during walking, using a (superficial) neurostimulator with tilt sensor.

Intervention type: DEVICE
Group type: OTHER
Intervention: FES
Description: Functional electrical stimulation of the ankle dorsiflexors during walking, using a (superficial) neurostimulator with tilt sensor.
Study: NCT03888131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo
Description: Fixed combination of beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg (BDP/FF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo
Description: Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (BUD/FF)
Study: NCT03949283

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ChemoID Assay
Description: The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill bulk of tumor cells, and cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ChemoID Assay
Description: The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill bulk of tumor cells, and cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse.
Study: NCT01027910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-24781
Description: Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle